cCam Biotherapeutics

cCAM Biotherapeutics is a preclinical stage company developing cancer immunotherapies. cCAM's lead agent, CM-10, is an immune-modulating antibody that harnesses the patient’s immune system to attack tumors. CM-10 binds to CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 eliminates this effect, resulting in a cancer-specific immune response in patients.